CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 78 enrolled
Drug / intervention
Pioglitazone +2 moredrug
Likely dose
Pioglitazone 45mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00736996
NCT00736996Phase 2Completed
CompareCT.gov

Pioglitazone and Exercise Effects on Older Adults With MCI and Metabolic Syndrome

University of Colorado, Denver·interventional·Posted Aug 18, 2008·Updated Jan 15, 2016

In Brief

A Phase 2 clinical trial evaluating Pioglitazone, Placebo, and 1 other intervention for Mild Cognitive Impairment. Completed, enrolled 78 participants across 1 site.

Detailed Summary

The purpose of this study is to investigate novel treatments to delay progression to dementia in patients with mild cognitive impairment (MCI) and metabolic syndrome (MS). The hypothesis is that treatment with pioglitazone or endurance exercise training will improve, stabilize, or attenuate decline in cognitive function compared to controls. This study will also discover potential mechanisms for the improvements and determine the baseline prevalence of amnestic versus non-amnestic MCI.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMild Cognitive Impairment
CountriesUnited States
CollaboratorsNational Institute on Aging (NIA)

Timeline

Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedAug 18, 2008
Enrollment StartNov 1, 2008
Primary CompletionDec 1, 2013
TodayJul 2, 2026
Enrollment to primary: 5.1 yearsPosted 17.9 years ago

Interventions

Pioglitazonedrug

30 - 45mg tablet daily for 6 months

Placebodrug

Matching tablet daily for 6 months

Endurance Exercise Trainingbehavioral

Individualized exercise prescription, 45-75 minutes (progressive increments) three times a week